Posters & Presentations 225Ac-DOTATATE (RYZ101) dosimetry results from Part 1 of the ACTION-1 Trial2023 SNMMI Annual MeetingACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2 expressing gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: initial safety analysis2023 ASCO Annual MeetingGPC3 targeted radiopharmaceutical therapy for HCC: Preclinical characterization of a novel peptide binder2023 EASL MeetingAnti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer2023 AACR Annual MeetingSurvival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome StudyJNM 2023
